JP2024506409A - 抗体 - Google Patents

抗体 Download PDF

Info

Publication number
JP2024506409A
JP2024506409A JP2023549559A JP2023549559A JP2024506409A JP 2024506409 A JP2024506409 A JP 2024506409A JP 2023549559 A JP2023549559 A JP 2023549559A JP 2023549559 A JP2023549559 A JP 2023549559A JP 2024506409 A JP2024506409 A JP 2024506409A
Authority
JP
Japan
Prior art keywords
tau
antibody
antigen
binding fragment
tau protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023549559A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506409A5 (cg-RX-API-DMAC7.html
Inventor
スターキー、デール
ジョン ライトウッド、ダニエル
Original Assignee
ユーシービー バイオファルマ エスアールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユーシービー バイオファルマ エスアールエル filed Critical ユーシービー バイオファルマ エスアールエル
Publication of JP2024506409A publication Critical patent/JP2024506409A/ja
Publication of JP2024506409A5 publication Critical patent/JP2024506409A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C07K2317/82—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies functional in the cytoplasm, the inner aspect of the cell membrane, the nucleus or the mitochondria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023549559A 2021-02-17 2022-02-15 抗体 Pending JP2024506409A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2102227.2A GB202102227D0 (en) 2021-02-17 2021-02-17 Antibodies
GB2102227.2 2021-02-17
PCT/EP2022/053694 WO2022175275A1 (en) 2021-02-17 2022-02-15 Antibodies

Publications (2)

Publication Number Publication Date
JP2024506409A true JP2024506409A (ja) 2024-02-13
JP2024506409A5 JP2024506409A5 (cg-RX-API-DMAC7.html) 2025-02-19

Family

ID=75338878

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023549559A Pending JP2024506409A (ja) 2021-02-17 2022-02-15 抗体

Country Status (5)

Country Link
US (1) US20240409624A1 (cg-RX-API-DMAC7.html)
EP (1) EP4294836A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024506409A (cg-RX-API-DMAC7.html)
GB (1) GB202102227D0 (cg-RX-API-DMAC7.html)
WO (1) WO2022175275A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026012596A1 (en) 2024-07-11 2026-01-15 Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) Biomarkers for differential diagnosis of frontotemporal dementia-amyotrophic lateral sclerosis-spectrum (ftd-als-spectrum)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018085653A1 (en) * 2016-11-04 2018-05-11 The Regents Of The University Of California Compositions targeting 3-repeat tau for the treatment of neurodegenerative disorders, and methods for making and using them
WO2019133799A1 (en) * 2017-12-29 2019-07-04 University Of Florida Research Foundation Monoclonal antibodies targeting microtubule-binding domain of tau protein

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018085653A1 (en) * 2016-11-04 2018-05-11 The Regents Of The University Of California Compositions targeting 3-repeat tau for the treatment of neurodegenerative disorders, and methods for making and using them
WO2019133799A1 (en) * 2017-12-29 2019-07-04 University Of Florida Research Foundation Monoclonal antibodies targeting microtubule-binding domain of tau protein

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ESPINOZA, M. ET AL.: "Differential Incorporation of Tau Isoforms in Alzheimer's Disease", JOURNAL ALZHEIMER'S DISEASE, vol. 14, no. 1, JPN6025052932, 1 May 2008 (2008-05-01), pages 1 - 16, ISSN: 0005765855 *

Also Published As

Publication number Publication date
EP4294836A1 (en) 2023-12-27
GB202102227D0 (en) 2021-03-31
WO2022175275A1 (en) 2022-08-25
US20240409624A1 (en) 2024-12-12

Similar Documents

Publication Publication Date Title
CN107847595B (zh) 特异性针对过度磷酸化τ蛋白的抗体及其使用方法
RU2760875C1 (ru) Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
JP6952827B2 (ja) 血液脳関門輸送分子およびそれらの使用
TWI673287B (zh) 抗b7-h3抗體、其抗原結合片段及其醫藥用途
AU2018370279B2 (en) Antibodies to a-synuclein and uses thereof
JP2021191763A (ja) シヌクレイノパチーの治療のための薬剤、使用および方法
EP3166688B1 (en) Tau imaging ligands and their uses in the diagnosis and treatment of tauopathy
CN113631573B (zh) 抗Tau抗体及其在制备用于治疗疾病的药物中的用途
JP6913078B2 (ja) タウの短縮型Ａｓｐ４２１エピトープに特異的な、抗体を基にした分子、ならびにタウ異常症の診断および治療におけるそれらの使用
JP6193275B2 (ja) Ｂ細胞媒介炎症性疾患を治療するための方法
JP7539834B2 (ja) ガレクチン－３に対する抗体及びその使用方法
JP2022506719A (ja) タウ認識抗体
JP2011514314A (ja) 抗体及びその誘導体
EP3555127B1 (en) Agents, uses and methods
US12365724B2 (en) Antibodies binding to phospho-tau comprising phosphorylated Ser396 and Ser404 and methods of detecting thereof
CN108137679A (zh) 对Tau的{p}Ser404表位有选择性的基于抗体的分子和它们在诊断和治疗Tau疾病中的用途
JP2024506409A (ja) 抗体
JP2025520651A (ja) 抗トランスサイレチン（ｔｔｒ）結合タンパク質及びその使用
HK40112455A (zh) Trem2抗原结合蛋白及其用途
TW202607018A (zh) 抗載脂蛋白ｅ４（ａｐｏｅ４）抗體及其用途
CN118284626A (zh) Trem2抗原结合蛋白及其用途
HK40022840B (zh) 抗α-突触核蛋白抗体及其用途
HK40013648A (en) Agents, uses and methods
HK40013648B (en) Agents, uses and methods
HK40018330B (zh) 治疗自身免疫疾病的结合fcrn的抗体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260406

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260414